Randomized controlled trials of treatments for hematologic malignancies: Study characteristics and outcomes

Cancer

Volumn 110, Issue 2, 2007, Pages 334-339

  Yanada, Masamitsu ^a,c   Narimatsu, Hiroto ^b   Suzuki, Takeshi ^c   Matsuo, Keitaro ^c   Naoe, Tomoki ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Hematologic malignancy; Primary end point; Randomized controlled trial; Study outcome

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; LEUKEMIA; LYMPHOMA; MEDLINE; MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

COHORT STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 34547206786     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22776     Document Type: Article

References (19)

1. Nottage M, Siu LL. Principles of clinical trial design. J Clin Oncol. 2002;20:42S-46S.
2. Stenning SP, Parmar MK. Designing randomised trials: both large and small trials are needed. Ann Oncol. 2002;13(suppl 4):131-138.
3. Roberts TG Jr, Lynch TJ Jr, Chabner BA. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol. 2003;21:3683-3695.
4. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol. 2003;21:4145-4150.
5. Chlebowski RT, Lillington LM. A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol. 1994;12:1789-1795.
6. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17:1794-1801.
7. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001;19:1734-1742.
8. Kumar A, Soares H, Wells R, et al. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ. 2005;331:1295.
9. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol. 2005;23:6982-6991.
10. Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst. 2000;92:1601-1607.
11. Freidlin B, Breathnach OS, Johnson BE. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2003;9:917-922.
12. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872.
13. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374-378.
14. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315:640-645.
15. Pich J, Carne X, Arnaiz JA, Gomez B, Trilla A, Rodes J. Role of a research ethics committee in follow-up and publication of results. Lancet. 2003;361:1015-1016.
16. Decullier E, Lheritier V, Chapuis F. Fate of biomedical research protocols and publication bias in France: retro-spective cohort study. BMJ. 2005;331:19.
17. Moher D, Fortin P. Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996;347:363-366.
18. Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290:516-523.
19. Zarin DA, Tse T, Ide NC. Trial Registration at Clinical Trials.gov between May and October 2005. N Engl J Med. 2005;353:2779-2787.